Aethlon Medical, Inc. (AEMD), a pioneering company in cancer and infectious disease therapies, has reported its fiscal Q1 2024 financial results, highlighting key corporate progress.
With a cash balance of $9.1 million as of June 30, 2024, Aethlon is well-positioned to drive forward its clinical initiatives.
Clinical Advancements for Hemopurifier® in Oncology
Aethlon’s Hemopurifier®, a blood filtration device targeting cancer exosomes and harmful viruses, received ethics approvals. The Bellberry Human Research Ethics Committee (BHREC) approved the Hemopurifier for an Australian clinical trial. Additionally, Central Adelaide Local Health Network (CALHN) granted approval for the same trial.
The trial is expected to begin patient enrollment in October 2024. The trial will assess the Hemopurifier’s efficacy in patients with solid tumors unresponsive to anti-PD-1 treatments. This includes widely-used therapies like Merck’s Keytruda® and Bristol Myers Squibb’s Opdivo®.
CHECK THIS OUT: Treace Medical (TMCI) Reports 11% Revenue Growth in Q3 2024
Strong Financials and Cost Efficiency Drive Q1 Performance
Aethlon reduced operating expenses by 24% year-over-year, totaling $2.6 million in Q1 2024, down from $3.4 million.
This decrease resulted from lower general, administrative costs, and professional fees, highlighting Aethlon’s commitment to cost efficiency in advancing clinical programs.
Expanding Research in Viral Infections
Beyond oncology, Aethlon is actively pursuing the Hemopurifier’s potential in treating life-threatening viral infections.
The device has shown promise in capturing viruses such as Zika, H1N1, and West Nile in preclinical studies, and the ongoing COVID-19 trial in India remains open for potential enrollment.
These findings reinforce Aethlon’s mission to address critical unmet needs in infectious disease treatment.
Aethlo’s strong financial position and recent clinical advancements create a solid foundation for growth in cancer and infectious disease therapies.
Aethlon’s expanding pipeline and regulatory momentum position it to make significant contributions to healthcare with its groundbreaking Hemopurifier® technology.
READ ALSO: Taysha Gene (TSHA) Reports Strong Q2 2024 Results and Advances TSHA-102 Trials and iHeartMedia (IHRT): Q2 Digital Growth Boosts Revenue.
